Use of a hybrid vaccinia virus-T7 RNA polymerase system for expression of target genes.
A novel expression system based on coinfection of cells with two recombinant vaccinia viruses has been developed. One recombinant vaccinia virus contained the bacteriophage T7 RNA polymerase gene under control of a vaccinia virus promoter. The second recombinant vaccinia virus contained a target gene of choice flanked by bacteriophage T7 promoter and termination sequences. Maximum expression of the target gene occurred when cells were infected with 10 PFU of each recombinant virus. Although T7 RNA polymerase synthesis began shortly after infection, the target gene was not expressed until late times and was largely inhibited when DNA replication was blocked. Target gene transcripts were analyzed by agarose gel electrophoresis and had the predicted size. With this system, Escherichia coli beta-galactosidase, hepatitis B virus surface antigen, and human immunodeficiency virus envelope proteins were made. In each case, the level of synthesis was greater than had previously been obtained with the more conventional recombinant vaccinia virus expression system.
D003001:Cloning, Molecular; D003561:Cytarabine / Q000494:pharmacology; D012321:DNA-Directed RNA Polymerases / Q000235:genetics*; D005786:Gene Expression Regulation / Q000187:drug effects; D005814:Genes, Viral; D005822:Genetic Vectors; D006514:Hepatitis B Surface Antigens / Q000235:genetics; D011401:Promoter Regions, Genetic; D011995:Recombination, Genetic; D014158:Transcription, Genetic; D014616:Vaccinia virus / Q000235:genetics*; D014759:Viral Envelope Proteins / Q000096:biosynthesis / Q000235:genetics; D001616:beta-Galactosidase / Q000096:biosynthesis / Q000235:genetics
D006514:Hepatitis B Surface Antigens; D014759:Viral Envelope Proteins; D003561:Cytarabine; D012321:DNA-Directed RNA Polymerases; D001616:beta-Galactosidase